Metastatic Non-Small Cell Lung Cancer: Current Standards and Emerging Therapies

Zhang, Jingyao; Deng, Lei

doi:10.53876/001c.130033

Submit an Article

Review Article

Vol. 6, Issue 1, 2026 · P1-18

Metastatic Non-Small Cell Lung Cancer: Current Standards and Emerging Therapies

Jingyao Zhang, MD, MSc,Lei Deng, MD

Non-small cell lung cancerMetastatic NSCLCFirst-line therapyTargeted therapyImmunotherapyMolecular profilingNovel agentsPrecision oncology

Submission received: 2025-10-22 / Accepted: 2026-03-20 / Published: 2026-04-09

CCBY-SA-4.0

Publication: IJCCDhttps://doi.org/10.53876/001c.130033

2

Sections

Abstract

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Advances in molecular diagnostics, immunotherapy, and targeted therapy have redefined the management of advanced NSCLC, establishing biomarker-guided treatment as the cornerstone of modern care. Comprehensive molecular profiling and PD-L1 testing are now essential to guide first-line therapeutic decisions. For patients without actionable mutations, chemoimmunotherapy or immune checkpoint inhibitor monotherapy provides durable survival benefits. For oncogene-driven disease, targeted agents against EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, HER2, and NTRK have markedly improved clinical outcomes. Novel therapies, including next-generation TKIs, antibody-drug conjugates, bispecific antibodies, and KRAS G12C, are expanding treatment options. This review synthesizes pivotal clinical trials and summarizes current evidence-based standards, presenting simplified treatment algorithms to guide decision-making in community oncology practice. It also discusses emerging agents and strategies that are expected to reshape first-line therapy in the coming years. Collectively, these developments continue to refine precision oncology and improve survival for patients with metastatic NSCLC.

Take Home Messages

1. Comprehensive molecular profiling and PD-L1 testing are essential for all patients with metastatic NSCLC to guide first-line therapy selection.

2. Targeted therapies for actionable mutations (EGFR, ALK, ROS1, BRAF, MET, RET, HER2, and NTRK) have transformed outcomes and improved survival.

3. For patients without actionable mutations, chemoimmunotherapy or immune checkpoint inhibitor monotherapy remains the standard of care.

4. Novel agents, including antibody-drug conjugates, bispecific antibodies, and next-generation TKIs, are expanding treatment options.

5. Ongoing research and clinical trial participation are critical to address resistance, refine treatment sequencing, and ensure equitable access to precision oncology.

1. Introduction

Lung cancer currently is responsible for approximately 1.8 million deaths each year worldwide and remains the number one cause of cancer-related deaths globally, accounting for about 18-19% of all cancer deaths. In the USA, lung cancer is responsible for approximately 125,000-127,000 deaths each year, accounting for about 20-22% of all cancer deaths.¹ In 2022, there were approximately 2.48 million new lung cancer cases worldwide and 1.8 million deaths associated with it, and the future burden is anticipated to be 4.62 million new cases and 3.55 million deaths associated with lung cancer by the year 2050, demonstrating the ongoing and increasing burden of this disease worldwide.² Non-small cell lung cancer (NSCLC) accounts for nearly 84% of lung cancers. About 44% of patients in the USA present with metastatic NSCLC at diagnosis, where prognosis remains dismal even with new therapeutics.³ In the United States, overall five-year survival has improved from 14% two decades ago to approximately 27% in recent years, yet remains only 6% for patients with distant disease.³

The decrease in mortality over the past decade is due to multiple factors: declining smoking prevalence, the use of low-dose CT screening, earlier diagnosis, and significant therapeutic progress with targeted therapies and immunotherapy.¹^, ⁴^-⁷ Despite this, disparities persist, with incidence and outcomes varying by sex, geography, socioeconomic position, and race/ethnicity.⁸^-¹⁰ Moreover, a rising proportion of NSCLC occurs in never-smokers, now accounting for up to 25% of cases in some series.¹¹^, ¹² These tumors are often driven by oncogenic alterations such as EGFR, ALK, or ROS1, highlighting the importance of comprehensive molecular profiling and targeted therapy.

This review outlines current standards for the management of metastatic NSCLC and highlights promising therapies that are likely to shape frontline treatment in the near future.

2. The importance of Comprehensive Molecular Profiling

Molecular profiling is central to metastatic NSCLC management, guiding targeted therapy selection that significantly improves survival.¹³^-¹⁵ Tissue biopsy remains the gold standard to provide histologic confirmation and high-quality DNA/RNA for next-generation sequencing (NGS), but it may be limited by procedural risk, sampling error, and insufficient tissue for broad molecular testing.¹⁶^-¹⁹ Liquid biopsy, which uses circulating tumor DNA (ctDNA), is a minimally invasive and complementary approach, enabling faster turnaround and higher sample success rates while capturing tumor heterogeneity.¹⁷^, ²⁰^-²⁶ However, liquid biopsy may yield false negatives in low-shedding tumors and has reduced sensitivity for detecting fusions or copy number changes.¹⁶^, ¹⁹^, ²⁵^, ²⁷^, ²⁸ To address these limitations, concurrent or reflex testing strategies, which initiate liquid biopsy when tissue is insufficient or delayed, are being implemented in practice.²⁰^, ²⁴^, ²⁵^, ²⁹ Broad-based NGS is recommended for all patients with advanced NSCLC, replacing sequential single-gene testing. DNA-based platforms effectively identify point mutations and small insertions or deletions, while RNA-based assays are crucial for detecting fusions and splice variants (e.g., ALK, ROS1, RET, NTRK, and MET exon 14 skipping), which may be missed by DNA-only approaches.³⁰^, ³¹ Comprehensive profiling should therefore integrate both DNA- and RNA-based methods to maximize detection of actionable alterations, including EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, HER2, KRAS G12C, and NTRK fusions.³⁰ In addition to genomic testing, immunohistochemistry (IHC) is also playing an increasing part in therapeutic selection. Beyond PD-L1, recently approved IHC-based biomarkers like HER2 IHC 3+ and c-MET overexpression have therapeutic implications, identifying candidates for emerging ADCs or MET-targeted therapies.³²^-³⁴ Combining NGS with IHC allows for full biomarker assessment, which guides precision treatment selection and clinical trial enrollment.

In community settings, turnaround time is crucial; rapid liquid biopsy NGS can provide early molecular results to guide treatment initiation while awaiting tissue confirmation.¹³^, ²²^, ³⁵ Beyond baseline profiling, ctDNA is also being investigated for minimal residual disease (MRD) detection, identification of acquired resistance mutations, and adaptive therapy guidance.²¹^, ²²^, ²⁵ These tools together define the foundation of precision oncology in NSCLC.

3. Frontline Therapy in Patients Without Actionable Drivers

The advent of immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) pathways has transformed the management of metastatic NSCLC lacking targetable driver alterations. Therapy selection in this setting requires a comprehensive assessment of molecular status, PD-L1 expression, disease burden, and patient comorbidities.³⁶^-³⁹ Before initiating immunotherapy-based treatment, all patients with newly diagnosed metastatic NSCLC should undergo testing for actionable genomic alterations, as targeted therapy remains superior to immunotherapy or chemotherapy for these subsets.⁴⁰^, ⁴¹ Only once oncogenic drivers are excluded or ruled out as treatment options should PD-L1 status guide subsequent therapeutic decisions.¹³

3.1 PD-L1 <50%: Chemoimmunotherapy

For patients without actionable driver mutations and with PD-L1 expression <50%, or when PD-L1 status is unknown, the combination of a PD-1/PD-L1 inhibitor with platinum-based chemotherapy remains the standard of care.³⁶^, ³⁷^, ⁴²^-⁴⁴ Histology remains an important determinant of regimen selection in this setting. In nonsquamous NSCLC, the pivotal KEYNOTE-189 trial demonstrated that pembrolizumab combined with pemetrexed and platinum chemotherapy significantly improved median OS compared with chemotherapy alone (22.0 vs 10.7 months; HR 0.56), with a sustained 5-year OS benefit of 19.4% versus 11.3%.⁴⁵ In squamous NSCLC, KEYNOTE-407 established pembrolizumab plus carboplatin and a taxane as a standard regimen, improving median OS to 17.1 months versus 11.6 months with chemotherapy alone (HR 0.71), with 5-year OS rates of 18.4% versus 9.7%.⁴⁶ EMPOWER-Lung 3, which enrolled both squamous and nonsquamous histologies, also confirmed the benefit of cemiplimab plus chemotherapy, with a median OS of 21.9 versus 13.0 months (HR 0.71).⁴⁷ Among nonsquamous regimens, IMpower150 provides an important alternative evidence-based option. In this phase III trial, atezolizumab combined with bevacizumab and platinum-based chemotherapy (ABCP) improved overall survival compared with bevacizumab plus chemotherapy alone (median OS 19.2 vs 14.7 months; HR 0.78) with consistent benefits in subgroups including those with liver metastases and STK11/KEAP1 co-mutations.⁴⁸ However, the IMpower151 trial, using a carboplatin–pemetrexed backbone in a Chinese population, did not meet its primary endpoint (median PFS 9.5 vs 7.1 months; HR 0.84).⁴⁹ Despite this, ABCP remains a guideline-endorsed option, particularly for liver metastases, though pembrolizumab-based regimens are preferred.

Dual immune checkpoint blockade (nivolumab + ipilimumab) also provides durable benefit across histologies and PD-L1 subgroups. In CheckMate 227, which enrolled both squamous and nonsquamous tumors, nivolumab plus ipilimumab improved median OS compared with chemotherapy (17.1 vs 13.9 months; HR 0.73; 95% CI 0.64–0.84) and showed consistent benefit across PD-L1 subgroups (<1%: HR 0.70; ≥50%: HR 0.70).⁵⁰ The CheckMate 9LA, which likewise included both histologies, showed that nivolumab plus ipilimumab with two cycles of platinum chemotherapy significantly improved OS compared with chemotherapy alone (15.6 vs 10.9 months; HR 0.66), with 5-6-year follow-up confirming durable benefit.⁵¹^-⁵³ Adding limited chemotherapy to dual immunotherapy reduces early progression and is suitable for patients with high disease burden or for those in whom prolonged chemotherapy is undesirable.⁴³^, ⁵¹^, ⁵⁴

3.2 PD-L1 ≥50%: ICI Monotherapy or Chemoimmunotherapy

For patients with high PD-L1 expression (≥50%), ICI monotherapy is an established standard. The KEYNOTE-024 trial demonstrated that pembrolizumab monotherapy significantly improved median OS compared with platinum-doublet chemotherapy (26.3 vs 13.4 months; HR 0.62), with a 5-year OS rate of 31.9% versus 16.3%.⁵⁵ EMPOWER-Lung 1 similarly showed a durable OS advantage for cemiplimab monotherapy (median OS 26.1 vs 13.3 months).⁵⁶

The choice between ICI monotherapy and chemoimmunotherapy depends on disease burden and clinical presentation. In patients with rapidly progressive or symptomatic disease, the addition of chemotherapy can accelerate response and reduce the risk of early progression.³⁷^, ⁵⁷^, ⁵⁸ For those with indolent disease or significant comorbidities, ICI monotherapy is often sufficient.⁵⁹ Notably, based on subgroup analysis, never-smokers may benefit less with ICI monotherapy, even with high PD-L1 expression; for these patients, chemoimmunotherapy is often favored to optimize efficacy and reduce early progression.⁵⁷^, ⁵⁸^, ⁶⁰^-⁶²

3.3 Choice of Chemotherapy Backbone

For most patients receiving chemoimmunotherapy, a carboplatin-based doublet is preferred due to its favorable toxicity profile, although cisplatin may be considered in younger, fit patients.⁶³ For nonsquamous histology, pemetrexed is the preferred partner, whereas for squamous histology, taxanes, gemcitabine, or vinorelbine are options.³⁶^, ⁴²^, ⁶⁴

3.4 STK11/KEAP1 Co-Mutations

Patients with STK11 or KEAP1 co-mutations exhibit poorer outcomes with ICI therapy. Retrospective analyses suggest resistance to PD-L1 monotherapy, and exploratory data indicate potential benefit from intensified strategies, such as dual ICI (PD-L1 + CTLA-4) with chemotherapy.³⁸^, ⁶⁵^-⁶⁷ While these co-mutations do not currently alter guideline-recommended therapy, they are important for prognostic discussions and ongoing clinical trial enrollment. The pivotal trials establishing first-line standards for NSCLC without actionable drivers are summarized in Table 1. A simplified treatment algorithm for metastatic NSCLC without targetable driver alterations is shown in Figure 1.

Figure 1. A diagram of a flowchart – Simplified treatment algorithm for metastatic NSCLC without targetable driver alterations

Table 1. Key Clinical Trials Defining First-Line Therapy in Metastatic NSCLC Without Actionable Drivers. Abbreviations: PFS, progression-free survival; OS, overall survival; 1L, first line.

Trial	Population (Histology / PD-L1)	Regimen (Experimental vs Control)	Primary Endpoints	Headline Results	Key Notes
KEYNOTE-189⁴⁵	Nonsquamous; all PD-L1	Pembrolizumab + pemetrexed + platinum vs chemo	OS, PFS	OS 22.0 vs 10.7 mo; HR 0.56; 5-yr OS 19.4% vs 11.3%	Standard for nonsquamous; benefit across PD-L1 strata.
KEYNOTE-407⁴⁶	Squamous; all PD-L1	Pembrolizumab + carboplatin + (paclitaxel or nab-paclitaxel) vs chemo	OS, PFS	OS 17.1 vs 11.6 mo; HR 0.71; 5-yr OS 18.4% vs 9.7%	Standard for squamous.
EMPOWER-Lung 3⁴⁶	Mixed histology; all PD-L1	Cemiplimab + platinum doublet vs chemo	OS, PFS	OS 21.9 vs 13.0 mo; HR 0.71	Another standard chemo-IO option.
IMpower150⁴⁸	Nonsquamous; all PD-L1	Atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) vs BCP	OS, PFS	OS 19.2 vs 14.7 mo; HR 0.78	Benefit in liver mets and STK11/KEAP1 subsets.
IMpower151⁴⁹	Nonsquamous (China); all PD-L1	Atezolizumab + bevacizumab + carboplatin + pemetrexed vs BCP + pemetrexed	OS, PFS	PFS 9.5 vs 7.1 mo; HR 0.84 (NS); OS 20.7 vs 18.7 mo; HR 0.93	No primary endpoint met; high EGFR prevalence; different chemo backbone.
CheckMate 9LA⁵¹^-⁵³	Mixed histology; all PD-L1	Nivolumab + ipilimumab + 2 cycles platinum chemo vs chemo	OS	OS 15.6 vs 10.9 mo; HR 0.66; durable 5–6-yr benefit	Dual ICI + limited chemo mitigates early progression risk.
CheckMate 227⁵⁰	Mixed histology; all PD-L1	Nivolumab + ipilimumab vs chemo	OS	OS 17.1 vs 13.9 mo; HR 0.73; benefit across PD-L1 subgroups	Chemo-free option for selected patients.
KEYNOTE-024⁵⁵	Mixed histology; PD-L1 ≥50%	Pembrolizumab vs platinum doublet	PFS (OS key secondary)	OS 26.3 vs 13.4 mo; HR 0.62; 5-yr OS 31.9% vs 16.3%	Establishes ICI monotherapy in PD-L1-high.
EMPOWER-Lung 1⁵⁶	Mixed histology; PD-L1 ≥50%	Cemiplimab vs chemo	OS	OS 26.1 vs 13.3 mo	Confirms PD-L1-high monotherapy option.

4. Frontline Therapy for Actionable Mutations

Targeted therapy has transformed metastatic NSCLC management, offering superior efficacy and tolerability in oncogene-driven disease. Identification of actionable driver alterations is therefore essential before treatment selection. Among these, alterations in EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, and RET are well-established therapeutic targets, while others such as HER2, KRAS G12C, and NTRK are rapidly emerging.³⁸^, ⁶⁸^-⁷⁰

EGFR Mutations

EGFR-activating mutations, primarily exon 19 deletions and L858R substitutions, are present in ~15-20% of NSCLC in Western populations and up to 40-50% in East Asian patients. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the standard first-line therapy based on the FLAURA trial, which demonstrated significantly longer PFS (18.9 vs 10.2 months; HR 0.46) and improved OS (38.6 vs 31.8 months; HR 0.80) compared with first-generation TKIs.⁷¹

Combination strategies are further extending outcomes. In FLAURA2, osimertinib plus platinum–pemetrexed improved PFS (25.5 vs 16.7 months; HR 0.62) and OS (47.5 vs 37.6 months; HR 0.77) versus osimertinib alone.⁷² The MARIPOSA trial evaluated the combination of amivantamab, a bispecific EGFR/MET antibody, with the third-generation TKI lazertinib versus osimertinib. Amivantamab plus lazertinib significantly improved PFS (median 23.7 vs 16.6 months; HR 0.70), and subsequently demonstrated a significant OS benefit (HR 0.75; P=0.005; 3-year OS 60% vs 51%).⁷³ Treatment selection should be individualized based on disease burden, toxicity, and CNS involvement. Patients with CNS metastases may particularly benefit from osimertinib-based approaches given its established intracranial activity. TP53 co-mutations are associated with poorer outcomes, although MARIPOSA showed benefit with amivantamab–lazertinib regardless of TP53 status.⁷³

EGFR exon 20 insertion mutations are a distinct subset associated with resistance to earlier-generation EGFR TKIs. In the phase III PAPILLON trial, first-line amivantamab plus carboplatin–pemetrexed improved PFS versus chemotherapy alone (11.4 vs 6.7 months; HR 0.40; ORR 73% vs 47%), establishing a new frontline standard.⁷⁴ Subsequent options include amivantamab monotherapy or the exon 20–targeted TKI sunvozertinib in previously treated patients.⁷⁵

ALK Rearrangements

ALK rearrangements occur in about 3-7% of NSCLC, often in younger, never-smoking patients.³⁷^, ⁷⁶ Next-generation ALK inhibitors have transformed outcomes, offering superior efficacy and CNS penetration compared with first-generation agents. The CROWN trial showed that lorlatinib significantly improved PFS compared with crizotinib, estimated 5-year PFS of 60% versus 8% (HR 0.28).⁷⁷ Lorlatinib also achieved robust intracranial responses, highlighting its superiority in preventing CNS progression.⁷⁷^-⁷⁹ Lorlatinib is associated with more toxicity, including hyperlipidemia, weight gain, and mood/psychotic changes. Early dose-reduction appears not to affect treatment outcomes. However, given the durable response, lorlatinib has been increasingly considered as the preferred first-line therapy for ALK-positive NSCLC.

ROS1 Rearrangements

ROS1 rearrangements happen in about 1–2% of NSCLC and are targetable with TKIs.³⁷^, ⁸⁰ First-generation TKIs (crizotinib, entrectinib) are established options with objective response rates (ORR) of 60–80% and median progression-free survival (PFS) of 15–20 months, but next-generation agents such as taletrectinib and repotrectinib offer enhanced CNS penetration and efficacy against resistance mutations.⁸⁰^-⁸³ The TRUST-I/II trials showed taletrectinib achieves ORR of 85–91% and robust intracranial activity, leading to its FDA approval as a preferred first-line therapy for ROS1-positive metastatic NSCLC.⁸⁴^-⁸⁷ Notably, taletrectinib appears to be associated much lower dizziness (~20%), due to its TRK-sparing structure. Current guidelines recommend taletrectinib, repotrectinib, entrectinib, or crizotinib as first-line options, with next-generation agents favored for patients with brain metastases or prior TKI resistance.

BRAF V600E Mutations

BRAF mutations are present in about 2-4% of NSCLC, with the V600E variant being the most common and associated with constitutive MAPK pathway activation.⁸⁸^-⁹¹ The combination of dabrafenib and trametinib established the standard of care, showing ORR around 64-68% and a median PFS of 10–11 months in both treatment-naïve and pretreated patients.⁹² More recently, the PHAROS trial showed that encorafenib plus binimetinib achieved comparable efficacy (ORR 75%, median PFS 11.1 months) and was better tolerated, which led to its approval as an alternative first-line option.⁹³ Current research is investigating optimal sequencing, resistance mechanisms, and potential synergy with immunotherapy to further improve outcomes in this molecular subset.⁹¹^, ⁹⁴^, ⁹⁵

MET Exon 14 Skipping

MET exon 14 skipping mutations and gene amplification occur in about 3-4% of NSCLC and represent actionable oncogenic drivers.⁹⁶ Selective MET inhibitors, including capmatinib and tepotinib, have shown robust efficacy, with ORR of 41-68% and median PFS of 8-12 months in the GEOMETRY mono-1 and VISION trials, respectively.⁹⁷^-⁹⁹ Both agents exhibit meaningful intracranial activity and are preferred first-line options for MET exon 14-mutated disease. Savolitinib has shown comparable results in East Asian populations, and combination strategies are currently being assessed.³⁴^, ⁹⁶

RET Rearrangements

RET fusions occur in approximately 1–2% of NSCLC, typically in younger, never-smoking patients with adenocarcinoma histology.¹⁰⁰ Selective RET inhibitors, selpercatinib and pralsetinib, are now the standard first-line therapies, demonstrating high efficacy and robust CNS activity. In the LIBRETTO-001 and LIBRETTO-431 trials, selpercatinib achieved ORR up to 85% and median PFS of 18–25 months, outperforming platinum-based chemotherapy and significantly reducing the risk of CNS progression, while pralsetinib produced comparable outcomes in the ARROW trial.¹⁰¹^-¹⁰⁴ Multikinase inhibitors are no longer preferred due to lower efficacy and higher toxicity, and ongoing research is focused on mechanisms of resistance and the development of next-generation RET-targeted therapies.¹⁰⁰^, ¹⁰⁵^, ¹⁰⁶

NTRK Fusions

NTRK gene fusions are rare, occurring in <1% of NSCLC, but represent highly actionable targets.³⁷ The selective TRK inhibitors larotrectinib and entrectinib produce ORR 57–75%, median PFS 10–35 months with durable benefit and CNS activity, leading to their tumor-agnostic FDA approval.¹⁰⁷^-¹⁰⁹ For patients who develop resistance, next-generation inhibitors such as repotrectinib and selitrectinib show promising efficacy. TRK inhibitors are recommended as first-line therapy for patients with NTRK fusion–positive NSCLC identified through comprehensive NGS.¹¹⁰

Targeted therapy has significantly improved outcomes for patients with actionable driver alterations, with many regimens now achieving median PFS exceeding two years. However, acquired resistance remains inevitable, highlighting the necessity of repeated molecular profiling at progression. Ongoing trials are investigating rational combination strategies, sequential therapy approaches, and novel agents to overcome resistance mechanisms and prolong survival further. An overview of approved first-line targeted therapies by genomic alteration is presented in Figure 2, complementing the data summarized in Table 2.

Figure 2. A diagram of a flowchart – Overview of approved first-line targeted therapies by genomic alteration in metastatic NSCLC

Table 2. Selected Approved First-Line Targeted Therapies for Oncogenic Drivers in Metastatic NSCLC. Abbreviations: ORR, objective response rate; PFS, progression-free survival; OS, overall survival; 1L, first line.

Oncogenic Driver	Estimated Prevalence	Approved First-Line Therapy	Key Trial(s)	Efficacy Highlights (approx.)	CNS Activity / Notes
EGFR (ex19del, L858R)	15–20% (West); 40–50% (East Asia)	Osimertinib	FLAURA⁷¹	PFS 18.9 vs 10.2 mo; OS 38.6 vs 31.8 mo vs 1st‑gen TKIs	High CNS penetration; preferred standard
		Osimertinib + Chemo	FLAURA2⁷²	PFS 25.5 vs 16.7 mo (HR 0.62); OS 47.5 vs 37.6 mo (HR 0.77)	Improvement of CNS activity
		Amivantamab + Lazertinib	MARIPOSA⁷³	PFS 23.7 vs 16.6 mo (HR 0.70); OS HR 0.75; 3-yr OS 60% vs 51%	Active in both 1L and pretreated; manageable toxicity
ALK fusions	3–7%	Lorlatinib	CROWN⁷⁷	HR for PFS 0.28 vs crizotinib; ~60% PFS at 5 yrs	Robust intracranial efficacy; prevents CNS progression
ROS1 fusions	1–2%	Taletrectinib, Repotrectinib; also Entrectinib or Crizotinib	TRUST‑I/II⁸⁴^-⁸⁷; TRIDENT‑1¹¹¹; STARTRK‑NG/2⁸¹	ORR typically 70–85%; median PFS often 15–24+ mo	Next‑gen agents have strong CNS activity and mutation coverage
BRAF V600E	2–4% (V600E subset)	Dabrafenib + Trametinib; Encorafenib + Binimetinib	BRF113928¹¹²; PHAROS⁹³	ORR ~60–75%; median PFS ~10–11 mo	Active in both 1L and pretreated; manageable toxicity
MET exon 14 skipping	3–4%	Capmatinib; Tepotinib	GEOMETRY mono‑1⁹⁷^, ⁹⁸; VISION⁹⁹	ORR 41–68%; median PFS ~8–12 mo	Meaningful intracranial activity; smoking agnostic
RET fusions	1–2%	Selpercatinib; Pralsetinib	LIBRETTO‑431¹⁰²; ARROW¹⁰³^, ¹⁰⁴	Selpercatinib PFS ~24.8 vs 11.2 mo vs chemo in 1L; ORR up to 85%	Both are CNS‑active; selective RET inhibitors preferred
NTRK fusions (TRK)	<1%	Larotrectinib; Entrectinib (tumor‑agnostic approvals)	NAVIGATE¹⁰⁷^, ¹⁰⁸; STARTRK‑2/NG¹⁰⁹	ORR ~57–75%; responses durable (many >12 mo)	CNS activity documented, especially with entrectinib

5. Post–Progression Strategies and Treatment Sequencing

Although first-line chemoimmunotherapy and targeted therapies have improved outcomes in metastatic NSCLC, most patients ultimately develop progressive disease. Treatment selection after progression should be individualized based on prior therapy, performance status, histology, and, when relevant, acquired resistance mechanisms.

5.1 Progression After Chemoimmunotherapy in Non-Actionable Disease

For patients without targetable driver alterations who progress after platinum-based chemoimmunotherapy, cytotoxic therapy remains the standard second-line approach. Docetaxel with or without ramucirumab is the most commonly used regimen. In the phase III REVEL trial, adding ramucirumab to docetaxel improved OS compared with docetaxel alone (10.5 vs 9.1 months; HR 0.86) and PFS (4.5 vs 3.0 months; HR 0.76).¹¹³ Real-world studies in the post–immune checkpoint inhibitor setting have shown consistent activity, with median overall survival ranging from approximately 11 to 21 months.¹¹⁴ Other cytotoxic options include pemetrexed for nonsquamous histology, nab-paclitaxel, or gemcitabine in selected patients.

ADCs are also expanding the salvage landscape and highlight the importance of reassessing tumor biology at progression. In the phase II LUMINOSITY study, telisotuzumab vedotin showed activity in previously treated, EGFR–wild-type, nonsquamous NSCLC with high c-MET overexpression, with an objective response rate of 35% and a median duration of response of 7.2 months.¹¹⁵ Trastuzumab deruxtecan has likewise demonstrated activity in HER2-overexpressing NSCLC, with confirmed ORRs of 26.5% to 34.1% in DESTINY-Lung01 and 44.4% with monotherapy in DESTINY-Lung03.¹¹⁶^-¹¹⁸

5.2 Strategies After Targeted Therapy Resistance

After progression on targeted therapy, management should be guided by the underlying driver alteration and resistance mechanism whenever possible. In EGFR-mutated disease, the phase III MARIPOSA-2 trial showed improved outcomes with amivantamab plus carboplatin–pemetrexed compared with chemotherapy alone (median PFS 6.3 vs 4.2 months; HR 0.48; intracranial PFS 12.5 vs 8.3 months), while the triplet regimen of amivantamab, lazertinib, and chemotherapy achieved a median PFS of approximately 8.3 months.¹¹⁹ Datopotamab deruxtecan is approved for EGFR-mutated metastatic NSCLC after prior EGFR-directed therapy and platinum chemotherapy, supported by TROPION-Lung05 (EGFR-mutated subgroup ORR 43.6%; pooled FDA ORR 45%, median duration of response 6.5 months). In TROPION-Lung01, it also improved PFS versus docetaxel (4.4 vs 3.7 months; HR 0.75), particularly in nonsquamous NSCLC (5.5 vs 3.6 months; HR 0.63).¹²⁰^, ¹²¹ In patients with MET amplification–mediated resistance, combinations such as osimertinib plus MET inhibitors have shown promising activity. In the phase III SACHI trial, osimertinib plus savolitinib achieved an ORR of 58% and significantly improved PFS compared with chemotherapy (8.2 vs 4.5 months; HR 0.34).¹²² The phase II INSIGHT-2 trial reported an ORR of approximately 50% with osimertinib plus tepotinib.¹²³ After progression in BRAF V600E– or MET exon 14–altered NSCLC, no validated targeted sequencing strategy has been established, and systemic chemotherapy or clinical trial enrollment is generally recommended.

5.3 Role of Re-biopsy and Repeat NGS

Repeat molecular profiling at progression is essential to identify resistance mechanisms and guide therapy. Plasma ctDNA provides a minimally invasive approach to detect emerging alterations, while tissue biopsy remains important when plasma testing is negative or transformation is suspected. In EGFR-mutated disease, this is particularly relevant because small-cell transformation occurs in approximately 5–10% of cases.¹²⁴ Combined plasma and tissue NGS improves detection of actionable resistance alterations.

6. Emerging Therapies and Future Directions

The treatment landscape of metastatic NSCLC is moving beyond single-pathway inhibition toward multi-targeted, biomarker-informed, and resistance-directed strategies. Several emerging approaches are likely to shape future treatment selection.

Bispecific antibodies are leading this shift. Amivantamab has already established proof of concept for dual EGFR/MET blockade in EGFR-mutant disease, while PD-1/VEGF bispecifics such as ivonescimab suggest that co-targeting immune and angiogenic pathways may further improve outcomes in driver-negative disease.¹²⁵^-¹²⁷

Next-generation ADCs and selective targeted agents are also expanding therapeutic options. Trastuzumab deruxtecan, telisotuzumab vedotin, and datopotamab deruxtecan further underscore the expanding role of ADCs across biomarker-selected and pretreated NSCLC, while zongertinib shows promise as a next-generation HER2-selective TKI.¹¹⁵^, ¹²⁸^, ¹²⁹ KRAS G12C inhibitors, including sotorasib and adagrasib, further highlight how rational combinations and earlier-line development may expand the impact of targeted therapy beyond the current second-line setting.¹³⁰^-¹³²

ICI combinations remain another important therapeutic strategy for future development. Dual-checkpoint and chemoimmunotherapy regimens have already shown durable benefit, and ongoing studies aim to refine patient selection and identify subgroups most likely to benefit from intensified immune strategies.⁵³^, ¹³³ Beyond these approaches, trispecific antibodies and other higher-order immune constructs are entering early clinical development.¹³⁴^-¹³⁶ Together, these advances are expected to further personalize NSCLC treatment and expand options for overcoming resistance. A summary of selected emerging therapeutic classes and representative agents is provided in Table 3.

Table 3. Emerging Therapeutic Strategies in Metastatic NSCLC

Class	Key Agents/Trials	Likely Role
EGFR/MET bispecifics	Amivantamab; MARIPOSA⁷³; MARIPOSA-2¹¹⁹; PAPILLON⁷⁴	Dual-pathway targeting in EGFR-driven disease
PD-1/VEGF bispecifics	Ivonescimab; HARMONi-2¹²⁷; HARMONi-6¹²⁶; HARMONi-A¹²⁵	Immune plus antiangiogenic blockade
HER2-directed ADCs/TKIs	Trastuzumab deruxtecan¹¹⁶; zongertinib¹²⁹; sevabertinib¹³⁷	Expanding HER2-directed sequencing
TROP2-directed ADCs	Datopotamab deruxtecan, TROPION studies¹²⁰^, ¹³⁸	Later-line and combination strategies
c-MET–directed ADCs	Telisotuzumab vedotin; LUMINOSITY¹¹⁵	Beyond MET exon 14 skipping
KRAS G12C combinations	Sotorasib, CodeBreaK studies; adagrasib, KRYSTAL studies¹³⁰; glecirasib + sitneprotafib¹³⁹	Earlier-line KRAS-directed strategies
Dual ICI regimens	CheckMate 9LA⁵¹^, ⁵³; POSEIDON¹³³	Refinement of immune intensification
Trispecific constructs	TAVO412¹³⁴; mesothelin TriKE¹³⁵; PD-L1/TIGIT/LAG-3 trispecifics¹³⁶	Next-generation immune engineering

7. Conclusion

The management of metastatic NSCLC has entered an era of molecular and immune precision, where therapy selection is increasingly driven by biomarker-defined subgroups. Broad-based next-generation sequencing, coupled with PD-L1 testing, forms the foundation of personalized care. Despite unprecedented survival gains, challenges remain in overcoming acquired resistance and ensuring equitable access to molecular diagnostics. Ongoing research into antibody–drug conjugates, next-generation immunotherapies, and rational combination strategies holds promise to further extend survival and potentially shift metastatic NSCLC toward a chronic, controllable disease.

References

1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45.

2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

3. Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021;7(12):1824-32.

4. Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81.

5. Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, et al. Lung cancer statistics, 2023. Cancer. 2024;130(8):1330-48.

6. Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncol. 2023;9(3):334-41.

7. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020;383(7):640-9.

8. Kurzrock R, Chaudhuri AA, Feller-Kopman D, Florez N, Gorden J, Wistuba, II. Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review. Cancer Metastasis Rev. 2024;43(4):1217-31.

9. Bade B, Faiz SA, Tan M, Baugh AD, Lavercombe M, Sheshadri A. The Impact of Health Care Disparities on Lung Cancer Screening and Treatment. Chest. 2025.

10. Shehata DG, Pan JM, Pan Z, Vigneswaran J, Contreras N, Rodriguez E, et al. Equity and Opportunities in Lung Cancer Care-Addressing Disparities, Challenges, and Pathways Forward. Cancers (Basel). 2025;17(8).

11. Díaz-Gay M, Zhang T, Hoang PH, Leduc C, Baine MK, Travis WD, et al. The mutagenic forces shaping the genomes of lung cancer in never smokers. Nature. 2025;644(8075):133-44.

12. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007;7(10):778-90.

13. Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review. JAMA. 2019;322(8):764-74.

14. Su PL, Furuya N, Asrar A, Rolfo C, Li Z, Carbone DP, et al. Recent advances in therapeutic strategies for non-small cell lung cancer. J Hematol Oncol. 2025;18(1):35.

15. Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, et al. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer. JAMA Network Open. 2023;6(12):e2347700-e.

16. Lin LH, Allison DHR, Feng Y, Jour G, Park K, Zhou F, et al. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas. Mod Pathol. 2021;34(12):2168-74.

17. Iams WT, Mackay M, Ben-Shachar R, Drews J, Manghnani K, Hockenberry AJ, et al. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. JAMA Network Open. 2024;7(1):e2351700-e.

18. Hofman P. Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives. Cancers (Basel). 2024;16(19).

19. Lin Z, Li Y, Tang S, Deng Q, Jiang J, Zhou C. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer. Lung Cancer. 2023;182:107282.

20. García-Pardo M, Czarnecka-Kujawa K, Law JH, Salvarrey AM, Fernandes R, Fan ZJ, et al. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial. JAMA Network Open. 2023;6(7):e2325332-e.

21. Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Int J Mol Sci. 2022;23(16).

22. Bertoli E, De Carlo E, Basile D, Zara D, Stanzione B, Schiappacassi M, et al. Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications. Int J Mol Sci. 2023;24(13).

23. Ospina AV. Overview of the Role of Liquid Biopsy in Non-small Cell Lung Cancer (NSCLC). Clin Oncol (R Coll Radiol). 2024;36(10):e371-e80.

24. Raez LE, Brice K, Dumais K, Lopez-Cohen A, Wietecha D, Izquierdo PA, et al. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2023;24(2):120-9.

25. Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology. 2022;40(11):1231-58.

26. Reina C, Šabanović B, Lazzari C, Gregorc V, Heeschen C. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer. Transl Res. 2024;272:41-53.

27. Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, et al. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid). Clin Cancer Res. 2023;29(8):1506-14.

28. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36(16):1631-41.

29. Bontoux C, Lacoux C, Benzaquen J, Boutros J, Rignol G, Long-Mira E, et al. Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site. J Exp Clin Cancer Res. 2025;44(1):229.

30. Owen D, Ben-Shachar R, Feliciano J, Gai L, Beauchamp KA, Rivers Z, et al. Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open. 2024;7(11):e2442970-e.

31. Ju S, Cui Z, Hong Y, Wang X, Mu W, Xie Z, et al. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer. Cancer. 2023;129(15):2422-30.

32. Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47-58.

33. Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R. Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol. 2022;84:184-98.

34. Lee JB, Shim JS, Cho BC. Evolving roles of MET as a therapeutic target in NSCLC and beyond. Nat Rev Clin Oncol. 2025;22(9):640-66.

35. Robert NJ, Espirito JL, Chen L, Nwokeji E, Karhade M, Evangelist M, et al. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. Lung Cancer. 2022;166:197-204.

36. Owen DH, Halmos B, Puri S, Qin A, Ismaila N, Abu Rous F, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1. J Clin Oncol. 2025;43(24):e45-e58.

37. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-54.

38. Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803-22.

39. Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625-44.

40. Li T, Ma W, Al-Obeidi E. Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer. Cancers (Basel). 2024;16(13).

41. Désage AL, Duruisseaux M, Lafitte C, Bayle-Bleuez S, Chouaid C, Fournel P, et al. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature. Cancer Treat Rev. 2024;129:102805.

42. Leighl NB, Ismaila N, Durm G, Florez N, Freeman-Daily J, Pellini B, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3. J Clin Oncol. 2025;43(10):e17-e30.

43. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024;42(11):e23-e43.

44. Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020;126(22):4867-77.

45. Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992-8.

46. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006.

47. Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, et al. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023;18(6):755-68.

48. Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909-24.

49. Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y, et al. Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nat Med. 2025;31(7):2375-84.

50. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020-31.

51. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211.

52. Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024;211:114296.

53. Carbone DP, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. ESMO Open. 2025;10(6):105123.

54. Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, et al. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. J Immunother Cancer. 2024;12(2).

55. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021;39(21):2339-49.

56. Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(9):989-1001.

57. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, et al. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun. 2023;14(1):695.

58. Di Federico A, De Giglio A, Gelsomino F, Sperandi F, Melotti B, Ardizzoni A. Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis. J Natl Cancer Inst. 2023;115(1):29-42.

59. Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2021;4(4):Cd013257.

60. Elkrief A, Alessi JMV, Ricciuti B, Brown S, Rizvi H, Preeshagul IR, et al. Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. J Immunother Cancer. 2023;11(7).

61. Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, et al. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 2022;33(5):511-21.

62. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-30.

63. Vasconcellos VF, Marta GN, da Silva EM, Gois AF, de Castria TB, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2020;1(1):Cd009256.

64. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2023;41(14):2458-66.

65. Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022;17(3):399-410.

66. Gandhi MM, Elkrief A, Moore CG, Ricciuti B, Alessi JV, Richards AL, et al. Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC. J Thorac Oncol. 2025;20(6):725-38.

67. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, et al. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024;635(8038):462-71.

68. Bazhenova L, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Halmos B, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. J Clin Oncol. 2024;42(36):e72-e86.

69. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022;40(6):611-25.

70. Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021;22(5).

71. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50.

72. Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935-48.

73. Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025.

74. Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389(22):2039-51.

75. Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, et al. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). J Clin Oncol. 2025;43(29):3198-208.

76. Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, et al. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. Cancers (Basel). 2022;14(19).

77. Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024;42(29):3400-9.

78. Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354-66.

79. Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J Clin Oncol. 2022;40(31):3593-602.

80. Desilets A, Repetto M, Yang SR, Drilon A. Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. Cancer. 2025;131 Suppl 1:e35784.

81. Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021;39(11):1253-63.

82. Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121-6.

83. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-71.

84. Li W, Xiong A, Yang N, Fan H, Yu Q, Zhao Y, et al. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol. 2024;42(22):2660-70.

85. Nagasaka M, Brazel D, Ou SI. Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data. Expert Opin Investig Drugs. 2024;33(2):79-84.

86. Pérol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, et al. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025;43(16):1920-9.

87. Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, et al. TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. Future Oncol. 2023;19(2):123-35.

88. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046-51.

89. Qu J, Shen Q, Li Y, Kalyani FS, Liu L, Zhou J, et al. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. Front Oncol. 2022;12:911303.

90. Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015;121(3):448-56.

91. Parisi C, Planchard D. BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice. Cancer. 2025;131 Suppl 1:e35781.

92. Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, et al. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol. 2022;17(1):103-15.

93. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023;41(21):3700-11.

94. Riudavets M, Cascetta P, Planchard D. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Lung Cancer. 2022;169:102-14.

95. Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, et al. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022;103:102335.

96. Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer. J Hematol Oncol. 2021;14(1):129.

97. Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024;25(10):1357-70.

98. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(10):944-57.

99. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020;383(10):931-43.

100. Marinello A, Ghigna MR, Rotow JK, Adeyelu T, Metro G, Brandão M, et al. Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer. JAMA Oncol. 2025;11(7):762-70.

101. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(9):813-24.

102. Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023;389(20):1839-50.

103. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959-69.

104. Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022;33(11):1168-78.

105. Servetto A, Esposito D, Ferrara R, Signorelli D, Belli S, Napolitano F, et al. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges. Biochim Biophys Acta Rev Cancer. 2022;1877(6):188810.

106. Mullally WJ, O'Leary CG, O'Byrne KJ. Rearranged during transfection (RET) lung cancer - Update on targeted therapies. Lung Cancer. 2025;200:108083.

107. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-9.

108. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531-40.

109. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-82.

110. Liu F, Wei Y, Zhang H, Jiang J, Zhang P, Chu Q. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance. Front Oncol. 2022;12:864666.

111. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390(2):118-31.

112. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307-16.

113. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-73.

114. Reuss JE, Bazhenova L, Ismaila N, Abu Rous F, Ahluwalia A, Alluri K, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0. J Clin Oncol. 2026;44(7):e56-e88.

115. Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, et al. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024;42(25):3000-11.

116. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022;386(3):241-51.

117. Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol. 2023;41(31):4852-63.

118. Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, et al. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. J Thorac Oncol. 2025:103541.

119. Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90.

120. Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G, Jr., Shum E, et al. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025;43(10):1254-65.

121. Parisi C, Mahjoubi L, Gazzah A, Barlesi F. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2023;118:102572.

122. Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2026;407(10526):375-87.

123. Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024;25(8):989-1002.

124. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019;37(4):278-85.

125. Investigators H-AS. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024;332(7):561-70.

126. Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025;406(10515):2078-88.

127. Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 2025;405(10481):839-49.

128. TSK M, YL W, L D, et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1. In: October, editor. ESMO Congress 2025; LBA74; Barcelona, Spain2025.

129. Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, et al. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025;392(23):2321-33.

130. Attili I, Corvaja C, Trillo Aliaga P, Del Signore E, Spitaleri G, Passaro A, et al. Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions. Cancer Treat Rev. 2025;137:102957.

131. Barlesi F, Yao W, Duruisseaux M, Doucet L, Martínez AA, Gregorc V, et al. Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025;406(10503):615-26.

132. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371-81.

133. Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023;41(6):1213-27.

134. Jin Y, Sun P, Chen P, Xu Y, Mu G, Zha Z, et al. A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models. Front Oncol. 2025;15:1533059.

135. Kennedy PR, Vallera DA, Ettestad B, Hallstrom C, Kodal B, Todhunter DA, et al. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Front Immunol. 2023;14:1060905.

136. Yang R, Huang S, Huang C, Fay NS, Wang Y, Putrevu S, et al. Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response. Sci Rep. 2023;13(1):9865.

137. Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, et al. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025;393(18):1819-32.

138. Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025;43(3):260-72.

139. Zhong J, Zhao J, Duan J, Fang J, Fei K, Li X, et al. Glecirasib plus sitneprotafib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial. Lancet Respir Med. 2026;14(2):163-73.